New hope for pancreatic cancer patients as experimental drug joins standard treatment
NCT ID NCT05497778
Summary
This early-stage study is testing whether adding a new drug called IM156 to standard chemotherapy (gemcitabine and nab-paclitaxel) is safe for people with advanced pancreatic cancer that has spread. Researchers will enroll 19 patients who haven't had previous treatment for their metastatic cancer to check for side effects and see if the combination might help control the disease better than chemotherapy alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.